3rd Quarter - Report

ALEXION PHARMACEUTICALS, INC. for ALEXION PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$275,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Trade Policy

LobbyistCovered position, as disclosed
GREGORY KALBAUGH —
HEIDI L WAGNER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

US Tax Reform Orphan Drug Tax Credit

LobbyistCovered position, as disclosed
LEIGH OWANO New —
VANESSA PROCTER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Intellectual Property Issues

LobbyistCovered position, as disclosed
LEIGH OWANO —
VANESSA PROCTER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Orphan Drug Act Drug Pricing ACA Repeal & Replace Right to Try Third party payments for co-pays and premium assistance RACE for Children Act

LobbyistCovered position, as disclosed
LEIGH OWANO New —
VANESSA PROCTER —
HEIDI L WAGNER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Medicare Inpatient Hospital Reimbursement Medicaid Reform Third party payments for co-pays and premium assistance

LobbyistCovered position, as disclosed
LEIGH OWANO New —
VANESSA PROCTER —
HEIDI L WAGNER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medical/Disease Research/Clinical Labs MED

PDUFA Reauthorization Right-to-Try Legislation RACE for Children Act

LobbyistCovered position, as disclosed
LEIGH OWANO —
VANESSA PROCTER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.